April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
In Vitro Antifungal Efficacy of Riboflavin/uva (365 Nm) Combination on Different Fungal Keratitis Isolates
Author Affiliations & Notes
  • T. Bourcier
    Ophthalmology, HUS - ULP, Strasbourg, France
  • V. Letscher-Bru
    Mycology, Faculté de Médecine - Université Louis Pasteur, Strasbourg, France
  • E. Candolfi
    Mycology, Faculté de Médecine - Université Louis Pasteur, Strasbourg, France
  • D. Gaucher
    Ophthalmology, HUS - ULP, Strasbourg, France
  • M. Saleh
    Ophthalmology, HUS - ULP, Strasbourg, France
  • D. Touboul
    Ophthalmology, CHU Bordeaux, Bordeaux, France
  • J. Colin
    Ophthalmology, CHU Bordeaux, Bordeaux, France
  • C. Speeg-Schatz
    Ophthalmology, HUS - ULP, Strasbourg, France
  • A. Sauer
    Ophthalmology, HUS - ULP, Strasbourg, France
    Mycology, Faculté de Médecine - Université Louis Pasteur, Strasbourg, France
  • Footnotes
    Commercial Relationships  T. Bourcier, None; V. Letscher-Bru, None; E. Candolfi, None; D. Gaucher, None; M. Saleh, None; D. Touboul, None; J. Colin, None; C. Speeg-Schatz, None; A. Sauer, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Bourcier, V. Letscher-Bru, E. Candolfi, D. Gaucher, M. Saleh, D. Touboul, J. Colin, C. Speeg-Schatz, A. Sauer; In Vitro Antifungal Efficacy of Riboflavin/uva (365 Nm) Combination on Different Fungal Keratitis Isolates. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To demonstrate the antimicrobial properties of riboflavin/UVA (365 nm) against fungal pathogens.

Methods: : The antimicrobial properties of riboflavin/UVA (365 nm) were tested on three groups of fungi selected from a panel of human keratomycosis isolates: Candida albicans (CA), Fusarium sp (FS) and Aspergillus fumigatus (AF). The antimicrobial properties were tested by using Kirby-Bauer discs with (1) empty disc (Control - C), (2) riboflavin 0.1% alone (R), (3) UVA alone for 1 hour (UVA), (4) riboflavin 0.1% and additionnal UVA exposure for 1 hour (R+UVA), (5) Amphotericin B alone (A), (6) Amphotericin B and riboflavin 0.1% (A+R), (7) Amphotericin B and UVA for 1 hour (A+UVA), and (8) Amphotericin B and riboflavin 0.1% and additionnal UVA exposure (A+R+UVA). The mean growth inhibition zone (GIZ) in square millimeters was measured around the discs. Descriptive statistics are expressed as mean and SD. A two-way ANOVA test was used for the analysis.

Results: : CA, FS and AF did not show any GIZ after treatment without previously Amphotericin B medication. However, the GIZ was significantly greater after riboflavin/UVA and pretreatment with amphotericine B (A+R+UVA) for CA (p=0,002), FS (p=0,007) and AF (p=0,03) when compared with A, A+R and A+UVA.

Conclusions: : Amphotericin B is believed to interact with fungi membrane sterols to produce aggregates that form transmembrane channels. Previously treatment with amphotericine B allowed Riboflavin/UVA effectiveness against CA, FS and AF. Further investigations are needed to determine in vivo efficacy of this therapeutic approach on severe keratomycosis.

Keywords: cornea: basic science • drug toxicity/drug effects • radiation damage: light/UV 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×